Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › BGM0504 phase 2 (China, obesity)

BGM0504 phase 2 (China, obesity)

BGM0504 · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
BGM0504
Population
obesity
Phase
2
Duration
24 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
BGM0504 5 mgobesity china24———−10.7 % vs +0.1 %
estimand not specified
———————verified
BGM0504 10 mgobesity china24———−16.1 % vs +0.1 %
estimand not specified
———————verified
BGM0504 15 mgobesity china24———−18.3 % vs +0.1 %
estimand not specified
———————verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (3)
  • BGM0504 5 mg · weight_unsp · Abstract
    Mean percentage changes in body weight from baseline to week 24 were -10.68%
  • BGM0504 10 mg · weight_unsp · Abstract
    Mean percentage changes in body weight from baseline to week 24 were -10.68%
  • BGM0504 15 mg · weight_unsp · Abstract
    Mean percentage changes in body weight from baseline to week 24 were -10.68%

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: BGM0504 phase 2 (China, obesity). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/bgm0504-phase-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.